01 abril 2016

JACC: CARDIOVASCULAR INTERVENTIONS. The Characteristics of In-Stent Restenosis After Drug-Eluting Stent Implantation in Femoropopliteal Lesions and 1-Year Prognosis After Repeat Endovascular Therapy for These Lesions

Osamu Iida, MDa; Mitsuyoshi Takahara, MD, PhDb,c; Yoshimitsu Soga, MD, PhDd; Keisuke Hirano, MDe; Yasutaka Yamauchi, MD, PhDf; Kan Zen, MD, PhDg; Daizo Kawasaki, MD, PhDh; Shinsuke Nanto, MD, PhDi; Hiroyoshi Yokoi, MDj; Masaaki Uematsu, MD, PhDa

Objectives: This study sought to investigate the characteristics of in-stent restenosis (ISR) after drug-eluting stent (DES) implantation for femoropopliteal (FP) lesions, and to examine 1-year prognosis after repeat endovascular therapy (re-EVT) for these DES-ISR.

01 mayo 2016

JACC: CARDIOVASCULAR INTERVENTIONS. 1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease. Evidence From the SFA-Long Study

Antonio Micari, MD, PhDa; Giuseppe Vadalà, MDa; Fausto Castriota, MDb; Armando Liso, MDc; Chiara Grattoni, MDb; Paolo Russo, MDd; Alfredo Marchese, MDe; Paolo Pantaleo, MDf; Giuseppe Roscitano, MDa; Bruno Mario Cesana, MDg; Alberto Cremonesi, MDb

Objectives: The aim of this study was to appraise 1-year outcomes after percutaneous treatment of long femoropopliteal artery disease using paclitaxel-coated balloons.

11 marzo 2016

CIRCULATION. Vascular Medicine. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery. 5-Year Results of the Zilver PTX Randomized Trial

Michael D. Dake, MD; Gary M. Ansel, MD; Michael R. Jaff, DO; Takao Ohki, MD; Richard R. Saxon, MD; H. Bob Smouse, MD; Lindsay S. Machan, MD; Scott A. Snyder, PhD; Erin E. O’Leary, PhD; Anthony O. Ragheb, PhD; Thomas Zeller, MD; on behalf of the Zilver PTX Investigators

Background: This randomized controlled trial evaluated clinical durability of Zilver PTX, a paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes compare primary DES versus percutaneous transluminal angioplasty (PTA), overall DES (primary and provisional) versus standard care (PTA and provisional Zilver bare metal stent [BMS]), and provisional DES versus provisional BMS.

08 septiembre 2015

CIRCULATION. Epidemiology and Prevention. Population-Based Study of Incidence, Risk Factors, Outcome, and Prognosis of Ischemic Peripheral Arterial Events

Dominic P.J. Howard, DPhil; Amitava Banerjee, DPhil; Jack F. Fairhead, MA; Linda Hands, FRCS; Louise E. Silver, DPhil; Peter M. Rothwell, FMedSci; on behalf of the Oxford Vascular Study

Background:There are few published data on the incidence and long-term outcomes of critical limb ischemia, acute limb ischemia, or acute visceral ischemia with which to inform health service planning, to monitor prevention, and to enable risk prediction.

14 octubre 2015

CIRCULATION. Vascular Medicine. Red Blood Cell Dysfunction Induced by High-Fat Diet. Potential Implications for Obesity-Related Atherosclerosis

Dusten Unruh, BS*; Ramprasad Srinivasan, PhD*; Tyler Benson, BA*; Stephen Haigh, BA; Danielle Coyle, MS; Neil Batra, BA; Ryan Keil, BS; Robert Sturm, BS; Victor Blanco, PhD; Mary Palascak, BA; Robert S. Franco, PhD; Wilson Tong, MD; Tapan Chatterjee, PhD; David Y. Hui, PhD; W. Sean Davidson, PhD; Bruce J. Aronow, PhD; Theodosia Kalfa, MD, PhD; David Manka, PhD; Abigail Peairs, PhD; Andra Blomkalns, MD; David J. Fulton, PhD; Julia E. Brittain, PhD; Neal L. Weintraub, MD*; Vladimir Y. Bogdanov, PhD*

Background: High-fat diet (HFD) promotes endothelial dysfunction and proinflammatory monocyte activation, which contribute to atherosclerosis in obesity. We investigated whether HFD also induces the dysfunction of red blood cells (RBCs), which serve as a reservoir for chemokines via binding to Duffy antigen receptor for chemokines (DARC).

05 noviembre 2014

CIRCULATION. Cardiovascular Surgery. Endovascular Treatment of Mycotic Aortic Aneurysms. A European Multicenter Study

Karl Sörelius, MD; Kevin Mani, MD, PhD; Martin Björck, MD, PhD; Petr Sedivy, MD, PhD; Carl-Magnus Wahlgren, MD, PhD; Peter Taylor, MA, MChir, FRCS; Rachel E. Clough, PhD, MRCS; Oliver Lyons, MRCS, PhD; Matt Thompson, MD, FRCS; Jack Brownrigg, MBChB, MRCS; Krassi Ivancev, MD, PhD; Meryl Davis, BSc, MBBS, FRCS; Michael P. Jenkins, BSc, MBBS, MS, FRCS, FEBVS; Usman Jaffer, BSc, MBBS, FRCS, MSc, PhD, PGCE, FHEA; Matt Bown, MD, FRCS; Zoran Rancic, MD, PhD; Dieter Mayer, MD; Jan Brunkwall, MD, PhD; Michael Gawenda, MD, PhD; Tilo Kölbel, MD, PhD; Elixène Jean-Baptiste, MD, PhD, FEBVS; Frans Moll, MD, PhD; Paul Berger, MD; Christos D. Liapis, MD, PhD; Konstantinos G. Moulakakis, MD, PhD, FEBVS; Marcus Langenskiöld, MD, PhD; Håkan Roos, MD; Thomas Larzon, MD, PhD; Artai Pirouzram, MD; Anders Wanhainen, MD, PhD; for the European MAA collaborators

Background: Mycotic aortic aneurysm (MAA) is a rare and life-threatening disease. The aim of this European multicenter collaboration was to study the durability of endovascular aortic repair (EVAR) of MAA, by assessing late infection–related complications and long-term survival.

13 noviembre 2014

CIRCULATION. Epidemiology and Prevention. Mortality From Thoracic Aortic Diseases and Associations With Cardiovascular Risk Factors

David Sidloff, MRCS, MBBS, BSc (Hon); Edward Choke, PhD, FRCS, MBBS; Philip Stather, MRCS, MBChB, MRCS; Matthew Bown, MD, FRCS, PGCert (Bioinformatics); John Thompson, PhD; Robert Sayers, MBChB (Hons), FRCS (Ed), FRCS (Eng), MD

Background: Temporal trends in mortality from thoracic aortic disease are unclear. This study examined trends in mortality from thoracic aortic aneurysm (TAA) and aortic dissection (AD) with the aim of identifying associations with trends in established cardiovascular risk factors.

03 diciembre 2014

CIRCULATION. Vascular Medicine. Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease. 12-Month Results From the IN.PACT SFA Randomized Trial

Gunnar Tepe, MD; John Laird, MD; Peter Schneider, MD; Marianne Brodmann, MD; Prakash Krishnan, MD; Antonio Micari, MD; Christopher Metzger, MD; Dierk Scheinert, MD; Thomas Zeller, MD; David J. Cohen, MD, MSc; David B. Snead, PhD; Beaux Alexander, MBA; Mario Landini, MS; Michael R. Jaff, DO; for the IN.PACT SFA Trial Investigators*

Background: Drug-coated balloons (DCBs) have shown promise in improving the outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated balloon with percutaneous transluminal angioplasty (PTA) for the treatment of symptomatic superficial femoral and popliteal artery disease.

19 septiembre 2014

CIRCULATION. Why Patients Know More About Cars Than Peripheral Artery Disease

Michael R. Jaff, DO, FACC

Americans who are interested in purchasing a motor vehicle often investigate automobile manufacturers, car models, and even competitive pricing using the World Wide Web. When one uses an Internet search engine to investigate Toyota, the largest automobile manufacturer in the world, there are >93 000 000 results. Virtually every possible question one would have about a Toyota vehicle is discoverable before ever visiting a local Toyota dealership.

01 agosto 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. New Techniques. Comparative Outcomes of Catheter-Directed Thrombolysis Plus Anticoagulation Versus Anticoagulation Alone in the Treatment of Inferior Vena Caval Thrombosis

Mohamad Alkhouli, MD, Chad J. Zack, MD, Huaqing Zhao, PhD, Irfan Shafi, MD and Riyaz Bashir, MD

Background: The contemporary practice patterns and role of catheter-directed thrombolysis (CDT) in the treatment of inferior vena cava thrombosis is unknown.

01 agosto 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Peripheral Vascular Disease. Ultrasound-Assisted Versus Conventional Catheter-Directed Thrombolysis for Acute Iliofemoral Deep Vein Thrombosis

Rolf P. Engelberger, MD, David Spirk, MD, Torsten Willenberg, MD, Adriano Alatri, MD, Dai-Do Do, MD, Iris Baumgartner, MD and Nils Kucher, MD

Background: For patients with acute iliofemoral deep vein thrombosis, it remains unclear whether the addition of intravascular high-frequency, low-power ultrasound energy facilitates the resolution of thrombosis during catheter-directed thrombolysis.

01 febrero 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Peripheral Vascular Disease. Percutaneous Transluminal Angioplasty and Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia (PADI) Trial

Marlon I. Spreen, MD, Jasper M. Martens, MD, Bettina E. Hansen, PhD, Bob Knippenberg, MD, PhD, Elke Verhey, Lukas C. van Dijk, MD, PhD, Jean-Paul P.M. de Vries, MD, PhD, Jan-Albert Vos, MD, PhD, Gert Jan de Borst, MD, PhD, Evert-Jan P.A. Vonken, MD, PhD, Jan J. Wever, MD, PhD, Randolph G. Statius van Eps, MD, PhD, Willem P.Th.M. Mali, MD, PhD and Hans van Overhagen, MD, PhD

Background: Endovascular infrapopliteal treatment of patients with critical limb ischemia using percutaneous transluminal angioplasty (PTA) and bail-out bare metal stenting (BMS) is hampered by restenosis. In interventional cardiology, drug-eluting stents (DES) have shown better patency rates and are standard practice nowadays. An investigator-initiated, multicenter, randomized trial was conducted to assess whether DES also improve patency and clinical outcome of infrapopliteal lesions.

01 febrero 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan. 12-Month Results

Hiroyoshi Yokoi, MDa; Takao Ohki, MD, PhDb; Kimihiko Kichikawa, MDc; Masato Nakamura, MD, PhDd; Kimihiro Komori, MD, PhDe; Shinsuke Nanto, MD, PhDf; Erin E. O’Leary, PhDg; Aaron E. Lottes, PhDg; Scott A. Snyder, PhDg; Michael D. Dake, MDh

Objectives: This multicenter, prospective, post-market surveillance study in Japan evaluates the paclitaxel-coated Zilver PTX stent in real-world patients with complex lesions.

01 enero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis. Initial Results From the EXCITE ISR Trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis)

Eric J. Dippel, MD∗; Prakash Makam, MD†; Richard Kovach, MD‡; Jon C. George, MD‡; Raghotham Patlola, MD§; D. Christopher Metzger, MD‖; Carlos Mena-Hurtado, MD¶; Robert Beasley, MD#; Peter Soukas, MD∗∗; Pedro J. Colon-Hernandez, MD††; Matthew A. Stark, PhD‡‡; Craig Walker, MD§§

Objectives: The purpose of this study was to evaluate the safety and efficacy of excimer laser atherectomy (ELA) with adjunctive percutaneous transluminal angioplasty (PTA) versus PTA alone for treating patients with chronic peripheral artery disease with femoropopliteal bare nitinol in-stent restenosis (ISR).

01 enero 2016

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Time-course of vascular dysfunction of brachial artery after transradial access for coronary angiography

Jerson Munoz-Mendoza MD1,*, Abhijit Ghatak MD2, Veronica Pinto Miranda MD3, Shaka Bahadu MD3, Eduardo De Marchena MD2, Alexandre C. Ferreira MD2,4 andCesar E. Mendoza MD4

Background: Prior studies have demonstrated endothelial and smooth muscle brachial artery dysfunction after transradial cardiac catheterization for diagnostic coronary angiography. The duration of this vascular dysfunction is unknown.